JAK inhibitors alleviate metabolic dysregulation, inflammation and fibrosis in osteoarthritis: insights from human joint cells and synovium

Tofacitinib and baricitinib modulate some features of OA pathophysiology by promoting anabolic processes in OA cartilage, reducing inflammation in OA synovium and attenuating some fibrotic factors in OA FLS. These findings demonstrate the potential use of tofacitinib and baricitinib as therapeutic options for managing OA, and highlight pathogenic pathways to target for further research and development of new OA treatment strategies.